Advertisement

FDA Approves Dapagliflozin for Type 2 Diabetes — Physician’s First Watch

Medical News |
January 9, 2014

FDA Approves Dapagliflozin for Type 2 Diabetes

By Amy Orciari Herman

Dapagliflozin (Farxiga) — an inhibitor of sodium-glucose co-transporter 2 — has been approved as an adjunct to diet and exercise in adults with type 2 diabetes, the FDA announced on Wednesday. The drug blocks the reabsorption of glucose by the kidney, thus decreasing blood glucose levels.

The approval comes with a series of caveats:

  • Dapagliflozin should not be used in patients on dialysis or those with moderate-to-severe renal impairment, end-stage renal disease, diabetic ketoacidosis, or type 1 diabetes.

  • It should not be used in those with active bladder cancer, as more bladder cancers were diagnosed in dapagliflozin users during clinical trials.

  • Dehydration may occur, which could lead to hypotension, dizziness, and declines in renal function.

  • The FDA is mandating six post-marketing studies to evaluate cardiovascular risk, bladder cancer risk, and safety and efficacy in children, among other outcomes.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement